Personalized care The medication is the smaller part Mochi pairs you with a physician, care team, pharmacist, and personalized plan designed to support your body, progress, and long-term goals over time
Do this every single time
Results: Oral semaglutide reduced HbA1c levels compared to placebo Oral semaglutide patients experienced significant weight loss compared to those on placebo The primary outcome (composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) occurred in 3.8% of patients in the oral semaglutide group and 4.8% in the placebo group, which showed that cardiovascular safety of oral semaglutide was non-inferior to placebo
For Wegovy pens (approved for weight loss), each pen is a single-dose autoinjector pre-filled with one specific dose: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, or 2.4 mg